[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis ErbB / Her Receptor Antagonists

July 2013 | 168 pages | ID: CB8AEFD7541EN
La Merie Publishing

US$ 853.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.

The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
  • Sales of Small Molecules Inhibitors of the ErbB/Her Receptor Family
  • Sales of Antibodies Targeting ErbB/Her Receptors
1) SMALL MOLECULES TARGETING THE ERBB/HER RECEPTOR FAMILY

a) Selective EGF-R Tyrosine Kinase (TK) Inhibitors
  Tarceva Pipeline
  Iressa Pipeline
  Pipeline of Other EGF-R Selective TK Inhibitors
b) Selective Her2 (ErbB2) TK Inhibitors
c) Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
  Tykerb Pipeline
  Pipeline of Other Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
d) Pan-Her (EGF-R, Her2 and Her4) / pan-Erb (ErbB1, ErbB2, ErbB4) TK Inhibitors
  Gilotrif Pipeline
  Neratinib Pipeline
  Dacomitinb Pipeline
  Poziotinib Pipeline
  Pipeline of Other Pan-Her Tk Inhibitors
e) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) Inhibition
f) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) and Her2 (ErbB2) Inhibition


2) BIOLOGICS (CELLS, PROTEINS, RNA) TARGETING THE ERBB/HER RECEPTOR FAMILY



3) VACCINES TARGETING THE ERBB/HER RECEPTOR FAMILY

a) EGF-R (ErbB1) Vaccines
b) Her2 (ErbB2) Vaccines
c) Her3 (ErbB3) Vaccines


4) ANTIBODIES TARGETING THE ERBB/HER RECEPTOR FAMILY

a) Selective EGF-R (ErbB1) Antibodies
  Erbitux Pipeline
  Vectibix Pipeline
  Nimotuzumab Pipeline
  Pipeline of Other Selective EGF-R (ErbB1) Antibodies
  Biosimilar Cetuximab Pipeline
  Biosimilar Panitumumab Pipeline
b) Selective Her2 (ErbB2) Antibodies
  Herceptin Pipeline
  Perjeta Pipeline
  Kadcyla Pipeline
  Pipeline of Other Selective Her2 (ErbB2) Antibodies
  Biosimilar Trastuzumab Pipeline
c) Selective Her3 (ErbB3) Antibodies
d) Dual and Pan ErbB / Her Antibodies
e) Dual Target Antibodies incl. ErbB/Her Receptor Antagonism


5) CORPORATE ERBB/HER RECEPTOR ANTAGONIST R&D PIPELINES


More Publications